NCT03667170 2026-03-25KN035 for dMMR/MSI-H Advanced Solid Tumors3D MedicinesPhase 2 Recruiting200 enrolled
NCT06321081 2024-03-20ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCBeijing HospitalPhase 2 Recruiting60 enrolled